EP1856522A1 - Dosages d'agents ayant une cytotoxicite selective envers les lignees cellulaires hdac-resistantes - Google Patents

Dosages d'agents ayant une cytotoxicite selective envers les lignees cellulaires hdac-resistantes

Info

Publication number
EP1856522A1
EP1856522A1 EP06709669A EP06709669A EP1856522A1 EP 1856522 A1 EP1856522 A1 EP 1856522A1 EP 06709669 A EP06709669 A EP 06709669A EP 06709669 A EP06709669 A EP 06709669A EP 1856522 A1 EP1856522 A1 EP 1856522A1
Authority
EP
European Patent Office
Prior art keywords
hdaci
resistant
test agent
inhibitor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06709669A
Other languages
German (de)
English (en)
Inventor
Torsten TopoTarget A/S NIELSEN
Nicholas TopoTarget UK Limited EDWARDS
Maxwell TopoTarget A/S SEHESTED
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Topotarget UK Ltd
Original Assignee
Topotarget UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget UK Ltd filed Critical Topotarget UK Ltd
Publication of EP1856522A1 publication Critical patent/EP1856522A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • TECHNICAL FIELD This invention pertains generally to the field of drug resistance, more particularly to cells resistant to inhibitors of histone deacetylases (HDACi), and specifically to cell lines resistant to the histone deacetylase inhibitor PXD101.
  • HDACi histone deacetylases
  • BACKGROUND DNA in eukaryotic cells is tightly complexed with proteins (histones) to form chromatin.
  • Histones are small, positively charged proteins which are rich in basic amino acids (positively charged at physiological pH), which contact the phosphate groups (negatively charged at physiological pH) of DNA.
  • the amino acid sequences of histones H2A, H2B, H3, and H4 show remarkable conservation between species, whereas H1 varies somewhat, and in some cases is replaced by another histone, e.g., H5.
  • Four pairs of each of H2A, H2B, H3, and H4 together form a disk-shaped octomeric protein core, around which DNA (about 140 base pairs) is wound to form a nucleosome.
  • nucleosomes are connected by short stretches of linker DNA associated with another histone molecule (e.g., H1 , or in certain cases, H5) to form a structure resembling a beaded string, which is itself arranged in a helical stack, known as a solenoid.
  • H1 histone molecule
  • H5 histone molecule
  • histones are synthesised during the S phase of the cell cycle, and newly synthesised histones quickly enter the nucleus to become associated with DNA. Within minutes of its synthesis, new DNA becomes associated with histones in nucleosomal structures.
  • a small fraction of histones, more specifically, the amino side chains thereof, are enzymatically modified by post-translational addition of methyl, acetyl, or phosphate groups, neutralising the positive charge of the side chain, or converting it to a negative charge.
  • lysine and arginine groups may be methylated
  • lysine groups may be acetylated
  • serine groups may be phosphorylated.
  • Methylation, acetylation, and phosphorylation of amino termini of histones which extend from the nucleosomal core affects chromatin structure and gene expression. (See, for example, Spencer and Davie, 1999). Acetylation and deacetylation of histones is associated with transcriptional events leading to cell proliferation and/or differentiation. Regulation of the function of transcription factors is also mediated through acetylation. Recent reviews of histone deacetylation include Kouzarides, 1999 and Pazin et al., 1997.
  • acetylases e.g., histone acetyltransferase, HAT
  • deacetylases e.g., histone deacetylase, HDAC
  • histone acetylation correlates with transcriptional activation
  • histone deacetylation is associated with gene repression.
  • HDACs histone deacetylases
  • the first deacetylase, HDAC1 was identified in 1996 (see, for example, Tauton et al., 1996).
  • HDAC2 and HDAC3 two other nuclear mammalian deacetylases has been found, HDAC2 and HDAC3 (see, for example, Yang et al., 1996, 1997, and Emiliani et al., 1998). See also, Grozinger et al., 1999; Kao et al., 2000; and Van den Wyngaert et al., 2000.
  • HDAC1 Genbank Accession No. NP_004955
  • HDAC2 Genbank Accession No. NP_0015178
  • HDAC3 Genbank Accession No. 015739
  • HDAC4 Genbank Accession No. AAD29046
  • HDAC5 Genbank Accession No. NP_005465
  • HDAC6 Genbank Accession No. NP_006035
  • HDACs 1 ,2,3 and 8 are in class I
  • HDACs 4,5,6 and 7 are in class II.
  • yeast There are a number of histone deacetylases in yeast, including the following: RPD3 (Genbank Accession No. NP_014069) HDA1 (Genbank Accession No. P53973) H0S1 (Genbank Accession No. Q12214) HOS2 (Genbank Accession No. P53096) HOS3 (Genbank Accession No. Q02959)
  • HDACs function as part of large multiprotein complexes, which are tethered to the promoter and repress transcription.
  • Well characterised transcriptional repressors such as Mad (Laherty et al., 1997), pRb (Brehm et al., 1998), nuclear receptors (Wong et al., 1998) and YY1 (Yang et al., 1997) associate with HDAC complexes to exert their repressor function.
  • Trichostatin A (Yoshida et al., 1990a) causes cell cycle arrest at both G1 and G2 phases (Yoshida and Beppu, 1988), reverts the transformed phenotype of different cell lines, and induces differentiation of Friend leukaemia cells and others (Yoshida et al., 1990b).
  • TSA and SAHA have been reported to inhibit cell growth, induce terminal differentiation, and prevent the formation of tumours in mice (Finnin et al., 1999).
  • TSA Trichostatin A
  • SAHA Suberoylanilide Hydroxamic Acid
  • TSA Cell cycle arrest by TSA correlates with an increased expression of gelsolin (Hoshikawa et al., 1994), an actin regulatory protein that is down regulated in malignant breast cancer (Mielnicki et al., 1999). Similar effects on cell cycle and differentiation have been observed with a number of deacetylase inhibitors (Kim et al., 1999). Trichostatin A has also been reported to be useful in the treatment of fibrosis, e.g., liver fibrosis and liver cirrhosis. See, e.g., Geerts et al., 1998.
  • TSA trichostatin A
  • SAHA suberoylanilide hydroxamic acid
  • phenylbutyrate has been reported to act, at least in part, by inhibiting histone deacetylase (see, e.g., Yoshida et al., 1990; Richon et al., 1998; Kijima et al., 1993).
  • diallyl sulfide and related molecules see, e.g., Lea et al., 1999), oxamflatin (see, e.g., Kim et al., 1999), MS-27-275, a synthetic benzamide derivative (see, e.g., Saito et al., 1999; Suzuki et al., 1999; note that MS-27-275 was later renamed as MS-275), butyrate derivatives (see, e.g., Lea and Tulsyan, 1995), FR901228 (see, e.g., Nokajima et al., 1998), depudecin (see, e.g., Kwon et al., 1998), and m-carboxycinnamic acid bishydroxamide (see, e.g., Richon et al., 1998) have been reported to inhibit histone deacetylases.
  • HDACs histone deacetylases
  • APL acute promyelocytic leukaemias
  • t(15;17) a translocation of chromosomes 15 and 17 results in the expression of a fusion protein containing the N-terminal portion of PML gene product linked to most of RAR ⁇ (retinoic acid receptor).
  • RAR ⁇ retinoic acid receptor
  • the wild type RAR ⁇ represses target genes by tethering HDAC repressor complexes to the promoter DNA.
  • retinoic acid binds RAR ⁇ and displaces the repressor complex, allowing expression of genes implicated in myeloid differentiation.
  • the RAR ⁇ fusion proteins occurring in APL patients are no longer responsive to physiological levels of RA and they interfere with the expression of the RA-inducible genes that promote myeloid differentiation. This results in a clonal expansion of promyelocytic cells and development of leukaemia.
  • HDACs may be important therapeutic targets in other types of cancer.
  • Cell lines derived from many different cancers prostate, colorectal, breast, neuronal, hepatic are induced to differentiate by HDAC inhibitors (Yoshida and Horinouchi, 1999).
  • HDAC inhibitors have been studied in animal models of cancer. They reduce tumour growth and prolong the lifespan of mice bearing different types of transplanted tumours, including melanoma, leukaemia, colon, lung and gastric carcinomas, etc. (Ueda et al., 1994; Kim et al., 1999).
  • One aspect of the invention provides a method to identify and/or obtain an agent which displays increased cytotoxicity to HDACi-resistant cells in comparison to the HDACi, said method comprising the steps of: incubating said HDACi resistant cells and sensitive cells with an agent to be tested; determining the cytotoxicity of said agent for HDACi resistant cells and sensitive cells; and, identifying agents which display a reduced resistance factor (IC50 value for resistant cells divided by IC50 value for parental cells) compared to the HDACi.
  • IC50 value for resistant cells divided by IC50 value for parental cells compared to the HDACi.
  • a further aspect of the invention provides a method to identify agents which display selective cytotoxicity to HDACi resistant cells in comparison to the HDACi, said method comprising the steps of: incubating said HDACi resistant cells and sensitive cells with an agent to be tested; determining the cytotoxicity of said agent for HDACi resistant cells and sensitive cells; and, identifying agents which display a resistance factor (IC50 value for resistant cells divided by IC50 value for parental cells) ⁇ 1.
  • the invention provides the agents identified according to the methods disclosed herein which are selectively cytotoxic to HDACi resistant cells.
  • Another aspect of the invention is a method to selectively inhibit the growth of HDACi resistant cells in vitro or in vivo, said method comprising contacting said resistant cells with one or more of said cytotoxic agents identified according to the methods disclosed herein.
  • Another aspect of the invention is a method to identify agents which are chemosensitizers of HDACi, said method comprising the steps of incubating HDACi resistant cells with the HDACi to which the cells are resistant, in the presence and absence of an agent to be tested and determining the cytotoxicity of the HDACi for the cells, wherein increased cytotoxicity in cultures incubated in the presence of the agent compared to cultures incubated in the absence of the agent indicates that the agent is a chemosensitizer.
  • the invention provides the chemosensitizers of HDACi's identified according to the methods disclosed herein.
  • the invention provides a method to inhibit the growth of HDACi resistant cells in vitro or in vivo, said method comprising contacting said HDACi resistant cells with one or more HDACi's and one or more of the chemosensitizers identified according to the method disclosed herein.
  • the invention provides a method to identify HDACi analogs, for example compounds with a mechanism of action similar to that of HDACi's, said method comprising the steps of contacting an HDACi resistant cell line and the corresponding HDACi sensitive parental cell line with increasing concentrations of a test substance; and, determining resistance of the HDACi resistant cell line to the test substance compared to resistance of the parental cell line to the test substance wherein greater resistance to the test substance of the HDACi resistant cell line compared to the parental cell line suggests that the test substance may act on the same signalling pathway as the HDACi.
  • the thus identified agents could include, but do not have to be restricted to, HDACi and their analogs.
  • the invention provides agents, including HDACi analogs, identified according to the method disclosed above herein are also herein included as an aspect of the invention.
  • This invention generally relates to HDACi resistant cell lines, such as HDACi resistant sublines of the P388 mouse leukemia cell line.
  • An HDACi resistant cell may be resistant to one or more HDACi, including, for example, PXD101 , trichostatin A (TSA), trapoxin, suberoylanilide hydroxamic acid (SAHA), phenylbutyrate, diallyl sulfide, oxamflatin, MS-27-275, butyrate, FR901228, depudecin, and m-carboxycinnamic acid bishydroxamide.
  • an HDACi resistant cell line may be resistant to PXD101 and may include the WT/PXD101-2C cell line described herein.
  • resistance of a cell to an agent refers to the ability of the cell to tolerate higher concentrations of a drug than a sensitive cell.
  • resistance of a cell that has been continually exposed to the PXD101 can be determined relative to the parental sensitive cell from which the drug resistant cell was derived. Resistance of a cell to an agent (e.g. PXD101) is typically quantitated as the increase in IC50 (concentration of the agent needed to inhibit cell growth by 50%) relative to a control sensitive cell,
  • test cells refers to cells that may or may not be PXD101 resistant.
  • One HDACi resistant cell line disclosed herein was obtained from culturing and subculturing P388 cell lines in the presence of increasing concentrations of PXD101.
  • the P388 cell line may be obtained from the ATCC (Manassas, VA, USA). This cell line may be grown in monolayer using RPMI supplemented with 10% fetal calf serum, 1 % L- glutamine, penicillin (50 Units/ml) and streptomycin (50 ⁇ g/ml) and maintained at 37°C in 5.0% CO2. Media and supplements are all available from Gibco Life Technologies, Rockville, MD.
  • the HDACi resistant P388/PXD101-C sub-line disclosed herein is derived from incubating the parental P388 breast adenocarcinoma cell line as above in PXD-101.
  • the term "subline” refers to a cell line that is derived from a parental cell line by virtue of its resistance to one or more HDACis. It is intended that the invention encompasses other PXD101 resistant cell lines that may be selected by culturing cells of the P388 cell line in the presence of other concentrations of PXD101.
  • the increase in fold resistance of the cell to PXD101 can be assessed relative to the parental cell line from which the resistant cell line was derived (e.g., IC50 of PXD101 for the resistant cell line versus IC50 of PXD101 for the parental cell line).
  • chemosensitizer of HDACis refers to a substance that can increase the efficacy of a therapeutic agent against a resistant cell and/or decrease the resistance of a cell for a therapeutic agent.
  • verapamil is a chemosensitizer of P-gp-mediated multidrug resistance; in the presence of verapamil, a multidrug resistant cell is more susceptible to the cytotoxic effect of anthracyclines.
  • the cell lines described herein are particularly useful in a method to identify substances that are chemosensitizers of HDACis.
  • Cytotoxicity can be measured using methods known to one of skill in the art, for example, a colorimetric assay system such as CELL TITER 96@ AQUEOUS assay (PROMEGA, Madison, Wl).
  • HDACi analog refers to a synthetic or natural compound that inhibits histone deacetylase activity.
  • cell lines described herein can be used to identify HDACi analogues that may partially overcome the resistance of cell lines for HDACis. For example, one could incubate an HDACi resistant cell line and corresponding parental cell line with increasing concentrations of a test substance and then determine the relative resistance factor by dividing the IC50 determined for the resistant cell line by that determined for the parental cell line. A test compound with a decreased resistance factor (compared to the HDACi included in the same assay as a reference) would constitute a potential analogue of interest
  • cytotoxic agent refers to compounds, including anticancer drugs, that inhibit cell proliferation and induce cell death.
  • the method could comprise incubating the resistant cell lines disclosed herein with the substance to be tested and, using standard methods, determining the cytotoxicity of the substance for the resistant cell line and comparing it to that of the parental cell line.
  • Compounds that preferentially kill HDACi-resistant cell lines, i.e. compounds where the IC50 for growth inhibition is lower on the resistant cells than on the corresponding parental cells would be a hit.
  • selectively cytotoxic agents include protein kinase C inhibitors such as staurosporine and DNA methylation inhibitors such as 5-azacytidine.
  • PKC Protein Kinase C
  • Phorbol esters bind and activate PKC and PKC has been implicated in phorbol ester-mediated responses such as the induction of differentiation markers in primary keratinocytes.
  • PKC inhibitors One of the most potent PKC inhibitors presently available is staurosporine (Tamaoki, T. et al, "Staurosporine, a potent inhibitor of phospholipid/Ca++ dependent protein kinase," Biochem. Biophys. Res.
  • PKC inhibitors include bryostatin I , tamoxifen, safingol, UCN-01 , CGP-41251 , bisindolylmaleimides such as GF109203X, calphostins, and antisense to PKC, such as ISIS3521 (reviewed in Da Rocha AB et al, "Targetting Protein Kinase C: New Therapeutic Opportunities against Malignant Glioma.” The Oncologist, 7(1): 17-33, 2002)
  • the DNA methylation inhibitors 5-azacytidine and decitabine are activated to a triphosphate and are degraded by cytidine deaminase.
  • 5-Azacytidine incorporates into RNA and, to a lesser extent, DNA.
  • Decitabine incorporates primarily into DNA.
  • Incorporation into RNA produces disassembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and marked inhibition of protein production. Insertion into DNA results in covalent linking with methyltransferase and blocking of DNA synthesis that ultimately results in direct cytotoxicity.
  • 5-Azacytidine is highly cytotoxic to cells in S phase and exerts its action mainly on rapidly dividing cells. (Reviewed in Santini et al "Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications" Ann. Int. Med 134:537-586, 2001)
  • the cytotoxic agents and chemosensitizers of HDACis identified according to the methods of the present invention are particularly useful in a method to inhibit the growth of HDACi resistant cell lines.
  • a method to inhibit growth of HDACi resistant cell lines using cytotoxic agents and chemosensitizers of HDACis would comprise contacting said HDACi resistant cells with one or more HDACis and one or more of the chemosensitizers.
  • a method to inhibit growth of HDACi resistant cell lines using cytotoxic agents identified according to the methods of the present invention would comprise contacting said resistant cells with one or more cytotoxic agents.
  • the term "contacting" is intended to include in vitro, ex vivo or in vivo administration.
  • cytotoxic agents and chemosensitizers identified according to the methods of the present invention may also be of therapeutic use in subjects bearing an HDACi resistant tumor (i.e., in situations where HDACis are not or no longer effective therapeutic agents due to natural or acquired resistance).
  • Suitable pharmaceutical compositions of such cytotoxic agents and chemosensitizers, methods of administration and dosages would be apparent to one of skill in the art and could be performed according to conventional methodologies, including those discussed below.
  • aspects of the invention provide the use of a PKC inhibitor and/or a DNA methylation inhibitor in the manufacture of a medicament for use in the treatment of an HDACi resistant cancer condition and a method of treating an HDACi resistant cancer condition in an individual comprising administering a PKC inhibitor and/or a DNA methylation inhibitor to the individual.
  • An HDACi resistant cancer condition may be resistant to PXD101.
  • a suitable PKC inhibitor may be selected from the group consisting of staurosporine, bryostatin I, tamoxifen, safingol, UCN-01 , CGP-41251 , bisindolylmaleimides, calphostins, PKC antisense molecules and analogues, derivatives or salts of any of these compounds.
  • the PKC inhibitor may be staurosporine or an analogue, derivative or salt thereof.
  • a suitable DNA methylation inhibitor may include 5-azacytidine, decitabine or an analogue, derivative or salt of either of these compounds.
  • a method may comprise the step of identifying the cancer condition as an HDACi resistant cancer condition.
  • a cancer condition may be identified as an HDACi resistant cancer condition using standard techniques.
  • HDACi resistant cells may be detected in a tumor sample in vitro or in vivo using conventional methods.
  • tumor tissue removed from a patient can be used as the tumor sample.
  • a sample can be used immediately or frozen and stored at temperature below -20°C for later use.
  • a tumor section on a microscope slide can be reacted with antibodies using standard immunohistochemistry techniques or with nucleic acids by standard in situ hybridization techniques.
  • tumor cells can be reacted with antibody and analyzed by flow cytometry.
  • an HDACi resistant tumor cell can be detected in vivo in a subject bearing a tumor.
  • Labelled antibodies can be introduced into the subject and antibodies bound to the tumor can be detected.
  • the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
  • Reagents useful for identifying an HDACi resistant tumor for example, antibodies specific for HDACi resistant cell antigens, can be incorporated into a diagnostic kit.
  • the kit can contain standards to which a sample is compared.
  • the various reagents can be included in the kit in suitable containers and the kit can include a holder for the containers as well as an instruction manual for the use of the kit.
  • the sensitivity of cancer cells from the individual to HDACi such as PXD101 , trichostatin A (TSA), trapoxin, suberoylanilide hydroxamic acid (SAHA), phenylbutyrate, diallyl sulfide, oxamflatin, MS-27-275, butyrate, FR901228, depudecin, or m-carboxycinnamic acid bishydroxamide may be determined in vitro.
  • compositions relate to the administration of a pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed herein.
  • Such pharmaceutical compositions may include, but are not limited to cytotoxic agents and chemosensitizers identified using methods described above.
  • pharmaceutical compositions may further comprise one or more HDACi.
  • compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water.
  • agent such as stabilizing compound
  • biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water.
  • compositions may be administered to a patient alone, or in combination with other agents, including other chemotherapeutic agents, drugs or hormones.
  • other chemotherapeutic agent refers especially to any chemotherapeutic agent that is or can be used in the treatment of tumor diseases, such as chemotherapeutics derived from the following classes: (A) Alkylating agents, preferably cross-linking chemotherapeutics, preferably bis-alkylating agents;
  • antitumor antibiotics preferably doxorubicin (ADRIAMYCINTM, RUBEXTM);
  • biological response modifiers preferably lymphokines or interferons
  • G inhibitors of protein tyrosine kinases and/or serine/threonine kinases;
  • H antisense oligonucleotides or oligonucleotide derivatives;
  • II microtubule stablizers/destabilizers; or
  • compositions encompassed by the invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-articular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.
  • these pharmaceutical compositions may contain pharmaceutically acceptable carriers or diluents comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • pharmaceutically acceptable carrier or diluent includes, but is not limited to, fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and binders, such as starch pastes using for example com, wheat, rice or potato starch, gelatin, tragacanth, methylcellulose, hydroxylpropylmethyl- cellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, also carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate.
  • fillers such as sugars, for example lactose, saccharose, mannitol or sorbitol
  • cellulose preparations and/or calcium phosphates
  • Excipients are especially flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol.
  • Dragee cores are provided with suitable, optionally enteric, coatings, there being used, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as ethylcellulose phthalate or hydroxypropylmethylcellulose phthalate.
  • Capsules are dry- filled capsules made of gelatin and soft sealed capsules made of gelatin and a plastiziser, such as glycerol or sorbitol.
  • the dry-filled capsules may comprise the active ingredient in the form of granules, for example with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and if desired with stabilizers.
  • the active ingredient is preferably dissolved or suspended in suitable oily excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols, and also stabilizers and/or antibacterial agents may be added. Dyes or pigments may be added to the tablets or dragee coatings or the capsule casings, for example for identification purposes or to indicate different doses of active ingredient.
  • therapeutically effective amount refers to that amount of active ingredient, for example an amount of antibodies raised against the HDACi resistant cell lines disclosed herein which when coupled to a substance having toxic or therapeutic activity, can ameliorate a symptom or condition e.g. cause the death of a tumor cell.
  • Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred.
  • the data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use.
  • the dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
  • the dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
  • the therapeutically effective amount can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs.
  • the animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • the exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks, or once every three weeks, depending on half-life and clearance rate of the particular formulation.
  • Cells were plated in 96-well plates at 3-10x103 cells/well in 100 ⁇ l_ of culture medium. The following day, different concentrations of candidate compounds were added and the cells incubated at 37 0 C for 48 h. Subsequently, 10 ⁇ L/well of WST-1 reagent was added and the cells reincubated for 1 hour. After the incubation time, absorbance was measured.
  • WST-1 is a tetrazolium salt which is cleaved to formazan dye by cellular enzymes.
  • An expansion in the number of viable cells results in an increase in the overall activity of mitochondrial dehydrogenases in the sample.
  • This augmentation in the enzyme activity leads to an increase in the amount of formazan dye formed, which directly correlates to the number of metabolically active cells in the culture.
  • the formazan dye produced is quantified by a scanning multiwell spectrophotometer by measuring the absorbance of the dye solution at 450 nm wavelength (reference wavelength 690 nm).
  • Percent activity (% activity) in reducing the number of viable cells was calculated for each test compound as:
  • % activity ⁇ (SC - B) / (S 0 - B) ⁇ x 100
  • SC denotes signal measured in the presence of the compound being tested
  • S° denotes signal measured in the absence of the compound being tested
  • B denotes the background signal measured in blank wells containing medium only.
  • the IC50 corresponds to the concentration which achieves 50% activity. IC50 values were calculated using the software package Prism 3.0 (GraphPad Software Inc., San Diego, CA) , setting top value at 100 and bottom value at 0.
  • the ratios of the IC50 of the parental P388 cell line (WT) to the HDACi resistant cell line (PXD-101-C) are as shown in the table below:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé d'identification et/ou d'obtention d'un agent sélectivement cytotoxique envers les cellules résistantes à l'inhibiteur de l'histone désacétylase (HDACi), ledit procédé comprenant les étapes consistant à: a) incuber des cellules résistantes à l'HDACi et des cellules sensibles à l'HDACi avec un agent à tester, b) déterminer la cytotoxicité de l'agent à tester vis-à-vis desdites cellules résistantes à l'HDACi et la cytotoxicité de l'agent à tester vis-à-vis desdites cellules sensibles à l'HDACi, une augmentation de la cytotoxicité de l'agent à tester vis-à-vis desdites cellules résistantes à l'HDACi par rapport auxdites cellules sensibles à l'HDACi indiquant que l'agent à tester est un agent sélectivement cytotoxique envers les cellules résistantes à l'HDACi. L'invention est basée sur l'acceptation du fait que les cellules qui sont résistantes aux inhibiteurs des histones désacétylases (HDACi) tels que PXD101, sont hypersensibilisées à certains agents anticancéreux.
EP06709669A 2005-02-07 2006-02-06 Dosages d'agents ayant une cytotoxicite selective envers les lignees cellulaires hdac-resistantes Withdrawn EP1856522A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65014105P 2005-02-07 2005-02-07
PCT/GB2006/000425 WO2006082448A1 (fr) 2005-02-07 2006-02-06 Dosages d'agents ayant une cytotoxicite selective envers les lignees cellulaires hdac-resistantes

Publications (1)

Publication Number Publication Date
EP1856522A1 true EP1856522A1 (fr) 2007-11-21

Family

ID=35978552

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06709669A Withdrawn EP1856522A1 (fr) 2005-02-07 2006-02-06 Dosages d'agents ayant une cytotoxicite selective envers les lignees cellulaires hdac-resistantes

Country Status (5)

Country Link
EP (1) EP1856522A1 (fr)
JP (1) JP2008529487A (fr)
AU (1) AU2006210994A1 (fr)
CA (1) CA2596405A1 (fr)
WO (1) WO2006082448A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627500T3 (es) 2012-07-13 2017-07-28 Turun Yliopisto Terapia de combinación
JP6294614B2 (ja) * 2013-05-08 2018-03-14 有限会社マイテック 癌関連物質の定量方法
CN107954893A (zh) * 2017-11-28 2018-04-24 兰州纬寰生物科技有限公司 邻氨基苯甲酰胺衍生物及制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
US20010053773A1 (en) * 1998-12-22 2001-12-20 The Procter & Gamble Company Method for inhibiting the growth of cancers
US20080233562A1 (en) * 2003-02-19 2008-09-25 Astellas Pharma Inc. Method of Estimating Antitumor Effect of Histone Deacetylase Inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006082448A1 *

Also Published As

Publication number Publication date
CA2596405A1 (fr) 2006-08-10
WO2006082448A1 (fr) 2006-08-10
AU2006210994A1 (en) 2006-08-10
JP2008529487A (ja) 2008-08-07

Similar Documents

Publication Publication Date Title
Mallorga et al. Mepacrine blocks beta-adrenergic agonist-induced desensitization in astrocytoma cells.
EP1427403B1 (fr) Acide valproique pour le traitement des cancers du sein, du colon, de la tête et du cou, du carcinome du poumon à petites cellules et du cancer de cellules sanguines en combinaison avec l'irradiation
US7126001B2 (en) Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US7550490B2 (en) Benzamide derivatives as histone deacetylase inhibitors with potent differentiation and anti-proliferation activity
US8236985B2 (en) Compounds and uses thereof
CN103764604B (zh) 茋类似物和治疗癌症的方法
BR112013005806B1 (pt) Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
CN105358549B (zh) 喹唑啉衍生物
CN111166742A (zh) 维生素e在谷氨酸脱氢酶获得功能突变治疗中的应用
EP1856522A1 (fr) Dosages d'agents ayant une cytotoxicite selective envers les lignees cellulaires hdac-resistantes
US7629364B2 (en) Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments
JP2011516473A (ja) 医薬組成物
WO2008068170A1 (fr) Inhibiteurs de l'hdac
Kim et al. KS10076, a chelator for redox-active metal ions, induces ROS-mediated STAT3 degradation in autophagic cell death and eliminates ALDH1+ stem cells
WO2011130395A1 (fr) Inhibiteurs de flip pour le traitement du cancer
JP2024023269A (ja) 抗腫瘍剤及び配合剤
US7351861B2 (en) Method and probe for identifying bacterial virulence modifying agents, agents thus identified, and their use
US20230129381A1 (en) Compositions and methods for treatment of anticancer-drug resistant cancers
Kortenhorst et al. Acetylation and histone deacetylase inhibitors in cancer
KR101400505B1 (ko) Ｐ５３ 기능을 대체하거나 작동시키는 소형 분자
WO2020230701A1 (fr) Agent antitumoral et agent de formulation
Kaypee et al. Emerging epigenetic therapies—Lysine acetyltransferase inhibitors
US9457016B2 (en) Methods for treating polycystic kidney disease
CN117756742A (zh) 苯并噻唑类化合物或其盐、其制备方法及应用
JP4150792B2 (ja) 血液脳関門におけるキノリン酸の輸送を評価する方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070905

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: EDWARDS, NICHOLAS,TOPOTARGET UK LIMITED

Inventor name: NIELSEN, TORSTEN

Inventor name: SEHESTED, MAXWELL,TOPOTARGET A/S

17Q First examination report despatched

Effective date: 20080201

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090708